Plain-English translation of NCT07682896 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called YB-101 to see if it can help treat Graves' disease, a condition where your immune system causes your thyroid to produce too much hormone. Researchers want to understand how safe the medication is, how your body processes it, and whether it actually helps control thyroid function. The study will enroll about 232 people and last roughly 40 weeks.
Graves' disease can cause serious symptoms and complications, and current treatment options don't work well for everyone. This trial is exploring whether this medication could offer patients a new, potentially better way to manage their condition.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll receive injections of either the new medication or a placebo (a dummy injection) under your skin. You'll attend 34 to 39 clinic visits over about 40 weeks, where doctors will check how you're doing, test your thyroid function, and monitor for any side effects. The study is divided into two parts, and you would participate in only one of them.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States